8 results
8-K
EX-99.1
SAVA
Cassava Sciences Inc
3 Aug 23
Cassava Sciences Reports Q2 2023 Financial Results and Operating Updates
9:12am
. Both Phase 3 studies have received a Special Protocol Assessment (SPA) from the U.S. Food and Drug Administration. Our Phase 3 studies recruit
10-K
EX-10.6
o26rlh99fsr9
22 Mar 02
Annual report
12:00am
- Prev
- 1
- Next